Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026

Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment

Definium shares are surging Monday after the company announced positive topline results from its Phase 3 Emerge study evaluating DT120 orally disintegrating tablet in adults with major depressive disorder — with the trial meeting its primary and all key secondary efficacy endpoints.

Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder

NEW YORK--(BUSINESS WIRE)--Jun 22, 2026-

Definium LSD therapy helped patients with major depression in late-stage trial

Definium Therapeutics said Monday that its LSD therapy significantly helped patients with major depression in its first Phase 3 trial, bringing the psychedelic drug closer to a potential approval. Six weeks after a single dose, patients on the pill, called DT120, experienced a 13.3-point drop on a depression test called the Montgomery-Åsberg Depression Rating Scale (MADRS), compared with a 5.2-point drop among patients taking placebo. By 12 week…

Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026

NEW YORK -- Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast tomorrow at 8 a.m. EDT to discuss topline results from Emerge, its first randomized, double-blind, placebo-controlled Phase 3 study evaluating a single dose…

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect

This morning, Definium Therapeutics announced positive topline results from its Phase 3 study of LSD (DT120) for major depressive disorder (MDD). It’s the first Phase 3 data for LSD, and for Definium. Source

Definium Therapeutics (DFTX) jumps in premarket on Phase 3 depression trial

Definium Therapeutics (DFTX) soared 64.2% pre-market to $40.19 after its Phase 3 Emerge trial showed DT120, an LSD-based tablet, achieved an 8.1-point placebo-adjusted benefit in major depressive disorder at week six, surpassing analyst expectations; investors now await results from a second trial and regulatory review, with approval and market access risks still ahead. The post Definium Therapeutics (DFTX) jumps in premarket on Phase 3 depressi…